Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Nov 25, 2020 7:34pm
185 Views
Post# 31975499

RE:Never felt better

RE:Never felt better
sghorb wrote: I already sold all my shares, last week right after the NR and price drop. 

We got some of the best news in the history of this company, and the stock didn't even fart. It actually went lower. Something I have only seen a few times in MY ENTIRE LIFE. 

What more news do you want? lol

I'm not saying this stock doesn't  have potential. But what is the point of staying here long when the stock will barely move. Don't worry you will have plenty of oppurtunities to buy in again. This stock is not the type of stock that reacts well. We saw proof. 

They say price target is 4$. Yes maybe, but not anytime soon. And even so, what do you think, it will jump there in a few weeks? come on lol. get real.

If this stock even reaches 1$ by Q1 2021, that is something I will consider good (for this company). But keep in mind this stock is not profitable, they are actually spending all the money they are getting. Yes I know that is a good thing, but not to share holders who want some decent returns within the next 6 months. Aristotle will need tons of money to market. Where is that money coming from? all this covid testing. 

Sold last week, and already up 15% in another stock this week. Anyway, just my 2 cents. 

I know some of you will get emotional about this. As expected. I'll buy in again when the SP is more reactive to positive news. I won't miss the train. Not the way this stock reacts. 




Balanced commentary and good luck to you - hopefully you get a few more 15 % returns.  However, I have seen lots of stocks produce a positive NR and not move - thats the way the market is these days. You are correct though that this one is reluctant to move much any given day/week - I attribute this to Tripp's many speculative predictions in the past that never panned out read: 30 million revenue prediction in last 6 months of last year etc. The market tired of this and now relies on actual numbers a la "show me the money variety". Fortunately for current investors, we are now at that point with real revenue, namming affiliations soon, more countries/states to sign on for covid testing, Aristotle roll out etc. - all to say that things are much different than in the past and when the right NRs come out we should quickly fulfill the Clarus $4.-- price prediction.  I may be wrong on all of this but if I am correct you may need a lot of 15% days to make up for the 600% this can climb.

<< Previous
Bullboard Posts
Next >>